Rationale: Sustained cardiac hypertrophy is often accompanied by maladaptive cardiac remodeling leading to decreased compliance and increased risk for heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. MicroRNAs (miRNAs) and long noncoding RNAs (lncRNAs) have various biological functions and have been extensively investigated in past years.
C ardiac hypertrophy is an adaptive reaction of the heart against cardiac overloading to maintain cardiac function at the early stage. However, sustained cardiac hypertrophy is often accompanied by maladaptive cardiac remodeling leading to decreased compliance and increased risk for heart failure and sudden death. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. Nevertheless, the underlying molecular mechanisms of cardiac hypertrophy are still poorly understood. To prevent heart failure, it is necessary to identify and characterize molecules that may regulate hypertrophy.
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MicroRNAs (miRNAs) are ≈22 nucleotides long and act as negative regulators of gene expression by inhibiting mRNA translation or promoting mRNA degradation. 1, 2 Growing evidence has demonstrated that miRNAs can play a significant role in the regulation of development, differentiation, proliferation, and apoptosis. [3] [4] [5] [6] miRNAs can regulate cardiac function including the conductance of electric signals, heart muscle contraction, heart growth, and morphogenesis. They also participate in the regulation of cardiac hypertrophy. 7, 8 Given the important role of miRNAs in the heart, it is necessary to identify those miRNAs that are able to regulate cardiac hypertrophy and to characterize their signal transduction pathways in hypertrophic cascades. miRNAs themselves are not hypertrophic executioners, they exert their effect through targeting hypertrophic genes. Although it has been reported that a variety of miRNAs can be altered during cardiac hypertrophy, 9, 10 the molecular targets of miRNAs still remain to be identified. Growing evidence has demonstrated that myeloid differentiation primary response gene 88 (Myd88) has an impact on cardiac pathology. Myd88 is related to myocardial infarction induced by ischemia/reperfusion, and knockout of Myd88 is able to reduce myocardial infarct sizes. 11, 12 There are a few reports showing that Myd88 is involved in hypertrophy. The blockade of MyD88 by adenoviruses expressing dominant negative Myd88 significantly reduces cardiomyocyte hypertrophy. 13 Fibrinogen induces hypertrophic response of cardiomyocytes partially through a toll-like receptor 4-mediated, Myd88-dependent nuclear factor-κB (NF-κB) pathway. 14 However, it is not yet clear whether Myd88 is a target of miRNAs in the hypertrophic machinery.
Long noncoding RNAs (lncRNAs) are transcribed RNA molecules >200 nucleotides in length but have no significant protein-coding potential. lncRNAs regulate the expression of genes at epigenetic, transcriptional, and post-transcriptional levels and play an important role in physiological processes. They have various functions such as RNA processing, 15 structural scaffolds, 16 modulation of apoptosis and invasion, 17 marker of cell fate, 18 reprogramming of induced pluripotent stem cells, 19 and chromatin modification. 20 In addition, lncRNAs can act as antisense transcripts or as decoys for splicing factors leading to splicing malfunctioning, 21, 22 and as a competing endogenous RNA in mouse and human myoblasts. 23 However, it is not yet clear whether ln-cRNA is involved in the regulation of cardiac hypertrophy.
Our present work aims at finding out miRNAs and lncRNAs that are able to regulate cardiac hypertrophy. miR-489 was found to be altered substantially in response to hypertrophic stimulation. In searching for downstream targets of miR-489, we identified that Myd88 can be regulated by miR-489. miR-489 affects cardiac hypertrophy through targeting Myd88. In exploring the mechanism how miR-489 expression is regulated, we identified that CHRF may act as an endogenous sponge that represses miR-489 activity. CHRF regulates Myd88 expression and consequent cardiac hypertrophy through miR-489. Our results reveal a novel hypertrophic regulating model that is composed of CHRF, miR-489, and Myd88.
Methods
Cell culture, quantitative RT-PCR analyses, Western blot analyses, adenoviral constructions and infection, transverse aortic constriction, histological assessments, and immunochemistry were performed according to routine protocols. Details of materials and methods are provided in the Online Data Supplement.
Statistical Analysis
Results are expressed as mean±SEM. Statistical comparison among different groups was performed by 1-way ANOVA. Two groups were evaluated by Student t test. P<0.05 was considered statistically significant.
Results

miR-489 Is Able to Inhibit Hypertrophy in the Cellular Model
Angiotensin II (Ang-II) has been well documented to induce cardiac hypertrophy. However, its underlying molecular mechanisms, including a possible role for miRNAs, remain to be elucidated fully. miRNA microarray analysis on cardiomyocytes identified significant downregulation of 9 miRNAs in response to Ang-II, including the evolutionary conserved miR-489 ( Figure 1A and 1B; Online Figure IA ). Ang-II-induced miR-489 downregulation in cardiomyocytes was confirmed by qRT-PCR ( Figure 1C ). We also detected the expression of miR-489 in different heart cell types. The expression of miR-489 was no different among myocytes, fibroblasts, and endothelial cells (Online Figure IB) . The expression of miR-489 was also significantly reduced in the transverse aortic constriction model in mice and human heart failure sample (Online Figure IC and ID). Because the cardiac function of miR-489 was unknown, we investigated its role in the heart under physiological and pathological conditions. In vitro miR-489 knockdown in cardiomyocytes using antagomirs (anta-489; Online Figure IIA ) promoted cardiomyocyte hypertrophy both at baseline and after Ang-II stimulation, as evidenced by increased cell surface areas (Online Figure  IIB) and protein/DNA ratios as a measure of protein synthesis (Online Figure IIC) . In contrast, the enforced expression of miR-489 (Online Figure IID) resulted in a reduction of hypertrophic responses, including cell surface area ( Figure 1D ), protein/DNA ratio ( Figure 1E ), hypertrophic marker atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC) ( Figure 1F ), and sarcomere organization ( Figure 1G ). These data suggest that miR-489 participates in antagonizing hypertrophy.
miR-489 Antagonizes Hypertrophy in the Animal Model
To better understand the function of miR-489 in the heart, we generated transgenic mice with cardiac-specific overexpressed miR-489. Five lines of miR-489 transgenic mice demonstrated a high level of miR-489 in the heart (Figure 2A ). miR-489 transgenic mice of Line#1 were used for the studies. We analyzed the phenotype of these mice under physiological conditions. These mice developed normally to adulthood without significant alterations in terms of hypertrophy ( Figure 2B ) and apoptosis (Online Figure IIIA) . Subsequently, we detected the hypertrophic responses of these mice in response to hypertrophic stimulation. miR-489 transgenic mice exhibited a reduced hypertrophic phenotype on Ang-II treatment (Online Figure  IIIB ; Figure 2C ). We also observed attenuation of other hypertrophic responses including cross-sectional area ( Figure 2D ), heart weight/body weight ratio ( Figure 2E ), and ANF, BNP, as well as β-MHC ( Figure 2F ). Concomitantly, cardiac function was ameliorated (Online Table I ). We also analyzed cardiac fibrosis and observed that it was reduced in miR-489 transgenic mice ( Figure 2G ). In addition, miR-489 mimic could increase Figure IVE) . Thus, it seems that miR-489 exerts an antihypertrophic function in the animal model.
Myd88 Is a Downstream Target of miR-489
miRNAs negatively regulate gene expression by inhibiting mRNA translation or promoting mRNA degradation. To find out the target gene of miR-489, we screened some hypertrophic associated genes (Cyclin T, GSK3β, PKGI, Ras, MYL2, CSRP3, MCIP1, Foxo3a, Calcineurin, NFAT, Myocardin, Myd88) by luciferase assay. We analyzed the 3ʹUTR of each mRNA sequence except Cyclin T (we analyzed the CDS region because of a lack of 3ʹUTR) by using the bioinformatics program RNAhybrid software. Approximately 200 bp fragments, including the best predicted binding sites of miR-489 from each target mRNA, were cloned into the pGL3 vector. Luciferase activity was detected. The results showed that miR-489 inhibited the luciferase activity of Myd88 (Online Figure VA ) and that it had no effect on other genes (data not shown). Myd88 has been reported to be involved in cardiomyocyte hypertrophy. 13, 14 However, it is not yet clear whether Myd88 is a target of miRNAs in the hypertrophic machinery.
The inhibitory effect of miR-489 on Myd88 3ʹUTR led us to consider if they are related in the hypertrophic pathway. We analyzed the 3ʹUTR region of Myd88 by RNAhybrid and noticed that miR-489 has a complementary sequence with Myd88 3ʹUTR ( Figure 3A ). To find out the binding sites of miR-489 to the 3ʹUTR of Myd88, mutations were introduced to Myd88 3ʹUTR and a mutated (mut) form was obtained ( Figure 3B ).
Luciferase assay revealed that miR-489 was able to suppress the luciferase activity of wild-type Myd88. However, the mutated form of Myd88 3ʹUTR demonstrated lesser response to miR-489 ( Figure 3C ). We tested whether miR-489 can regulate Myd88 levels. Enforced expression of miR-489 led to a reduction of Myd88 on Ang-II treatment ( Figure 3D ). The knockdown of endogenous miR-489 induced an increase in Myd88 expression ( Figure 3E ). In contrast, enforced expression of miR-489 resulted in a reduction of endogenous Myd88 ( Figure 3F ). In human cell line HEK293, we also got similar results (Online Figure The expression of miR-489 was analyzed by qRT-PCR from wild type (WT) and different lines of miR-489 Tg mice, and the results were normalized to that of U6. B, miR-489 Tg mice developed normally without obvious phenotype alterations under basal conditions (bar, 20 μm). Heart weight to body weight ratios (n=16). Histological sections were stained with wheat germ agglutinin-FITC conjugate to determine cell size. Fractional shortening (n=10 per group). C to F, miR-489 Tg mice exhibit reduced hypertrophic responses to angiotensin II (Ang-II) infusion. WT and miR-489 Tg mice were infused with Ang-II. C, Gross hearts (top; bar, 2 mm); heart sections stained with hematoxylin and eosin (middle; bar=2 mm; bottom; bar, 20 μm). D, Cross-sectional areas analyzed by staining with TRITCconjugated wheat germ agglutinin; *P<0.05. E, The ratios of heart weight to body weight; *P<0.05 vs Ang-II plus WT. F, Expression levels of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC); *P<0.05 vs Ang-II plus WT. G, miR-489 Tg mice exhibited reduced cardiac fibrosis in response to Ang-II infusion. WT and miR-489 Tg mice were infused with Ang-II. Masson trichrome staining for collagen; *P<0.05; bar, 20 μm.
To verify the interaction between miR-489 and Myd88 3ʹUTR in vivo, we performed biotin-labeled miR-489 pulldown assay to test whether miR-489 could pull down Myd88 in vivo. Cardiomyocytes were transfected with biotinylated wild-type miR-489 (Bio-489-wt) or its mutated form (Bio-489-Myd88-mut; Online Figure VIA ) and then harvested for biotin-based pulldown assay. Myd88 was pulled down by wild-type miR-489. The mutated form that disrupts basepairing between Myd88 3ʹUTR and miR-489 significantly reduced the ability to pull down Myd88 (Online Figure VIB) , indicating that the interaction between miR-489 and Myd88 3ʹUTR actually exists in vivo. We further explored the relationship between endogenous miR-489 and Myd88 in RNAinduced silencing complex in vivo. It is well known that Ago2 is the catalytic center of RNA-induced silencing complex, 24 and it associates with small regulatory RNAs that silence target RNAs through partial base-pairing. 25 Also, Ago2 immunoprecipitation can pull down non-seed-pairing target as previously reported. 26, 27 And the nonseed target is also regulated by miRNA. 28 Thus, we used Ago2 to explore the interaction between endogenous miRNAs and mRNAs in RNA-induced silencing complex in vivo. First, we conducted immunoprecipitation in mouse heart lysates with Ago2 antibody. Next we performed further affinity purification using biotin-labeled probes that are complementary to the 3ʹUTR region of Myd88 to pull down endogenous miR-489 (Online Figure VIC) . We synthesized 3 probes, 1 of which is complementary to the 3ʹUTR region of Myd88 and is also the binding site of miR-489 (P-BS 489 ). The other 2 probes are located outside the binding site of miR-489 (P1 and P2). A random probe that is not complementary to Myd88 was used as a negative control. Our results showed that probes outside the binding site of miR-489 could pull down miR-489, whereas the probe in the binding site could not (Online Figure VID) . In addition, we also detected miR-489 from argonaute complexes after Ang-II treatment. The argonaute complexes were obtained by immunoprecipitation using the Ago2 antibody. As shown in Online Figure VIE , Ang-II treatment led to a reduction in the enrichment of miR-489 from argonaute complexes. Taken together, these results indicate that there is a direct interaction between endogenous miR-489 and Myd88 in RNA-induced silencing complex in vivo.
Furthermore, we attempted to investigate whether miR-489 and Myd88 are functionally related in hypertrophy. To this end, we used the target protector technology in which a target protector is able to disrupt the specific interaction of miRNA-mRNA pairs. 29 The target protector of Myd88 was able to augment the expression levels of Myd88 in the presence of miR-489 ( Figure 3H, upper panel) . Concomitantly, miR-489 could not significantly suppress hypertrophic responses in the presence of Myd88 target protector ( Figure 3H , lower panel). Together, these data suggest that miR-489 exerts its effect through Myd88.
Myd88 Conveys Hypertrophic Signal
Next, we tested Myd88 expression levels on Ang-II treatment and observed that there was an increase ( Figure 4A ). The expression levels of Myd88 were also significantly increased in the heart of transverse aortic constriction mouse model (Online Figure VIIA) and human heart failure sample (Online Figure VIIB) . The knockdown of Myd88 attenuated hypertrophic responses revealed by cell surface area measurement ( Figure 4B ), analysis of protein/DNA ratio, and ANF, BNP, as well as β-MHC ( Figure 4C ). Myd88 often has NF-kB as downstream effector, and so we also detected the activity of NF-κB. Our results showed that Ang-II treatment can active the NF-κB system ( Figure 4A and 4B) . To further explore the role of Myd88 in hypertrophy, we used Myd88-knockout mice. In response to Ang-II treatment, Myd88-knockout mice exhibited a reduced hypertrophic phenotype ( Figure 4D ) and heart weight/body weight ratio ( Figure 4E) . The crosssectional area ( Figure 4F) and ANF, BNP, as well as β-MHC ( Figure 4G) were attenuated in Myd88-knockout mice. We observed a preserved cardiac function in Myd88-knockout mice ( Figure 4H ). Furthermore, cardiac fibrosis was reduced in Myd88-knockout mice ( Figure 4I ). Myd88 is an inflammatory mediator, and inflammation is a known player in pressure overload-driven cardiac hypertrophy. 30 Our results showed that Myd88-knockout mice also exhibit attenuated inflammatory response to proinflammatory Ang-II (Online Figure VIIC and VIID). Taken together, the results suggest that Myd88 is a prohypertrophic factor. To further explore whether miR-489 exerts its effect through Myd88 in vivo, we tested the effects of miR-489 in Myd88-knockout mice. The administration of miR-489 mimic or antagomir was able to alter miR-489 levels on Ang-II treatment (Online Figure VIIIA) . However, the hypertrophic phenotype (Online Figure VIIIB) , heart weight/ body weight ratio (Online Figure VIIIC) , and cross-sectional area (Online Figure VIIID) were not influenced by altering miR-489 levels in Myd88-knockout mice.
CHRF Is Able to Regulate miR-489 Expression and Activity
How is miR-489 expression regulated under pathological conditions? Recent studies have suggested that lncRNAs may act as endogenous sponge RNA to interact with miRNAs and influence the expression of miRNA. 23, 31, 32 To understand which lncRNA is involved in the hypertrophic pathway of Ang-II treatment, we screened 100 lncRNAs with moderate expression level in heart from a result of lncRNA array performed by Affymetrix Company. We performed real-time RT-PCR to detect lncRNA levels in response to Ang-II treatment. Among the lncRNAs, AK048451, which we named CHRF, was substantially elevated ( Figure 5A ). CHRF is located in the first intron of Dcc (deleted in colorectal carcinoma) in mouse, and the length is 1843 nt (Online Table II ). The expression level of CHRF is more than one third of miR-489 in mouse heart (Online Figure IXA) , and it is no different among myocytes, fibroblasts, and endothelial cells (Online Figure IXB) . CHRF is also widely expressed in various tissues (Online Figure IXC) , and it is conserved across species in the binding site of miR-489 (Online Figure XA) . Ang-II treatment led to a time-dependent elevation of CHRF levels ( Figure 5B ). CHRF was also significantly increased in the heart of transverse aortic constriction mouse model (Online Figure XB) and human heart failure sample (Online Figure XC) . miR-489 levels were elevated in the cells on knockdown of endogenous CHRF (Figure 5C and 5D ). To know whether CHRF can affect miR-489 activity, we constructed a miR-489 sensor ( Figure 5E, upper panel) . The miR-489 sensor construct contains a perfect miR-489 target, and a reduced luciferase activity of the sensor indicates the induction of miR-489 activity. Our results showed that the lucifease activity of miR-489 sensor was decreased in cells treated with CHRF siRNA ( Figure 5E , lower panel), suggesting the induction of miR-489 activity. Enforced expression of CHRF ( Figure 5F ) induced a reduction in miR-489 levels ( Figure 5G ) and miR-489 activity ( Figure 5H ). Furthermore, we wanted to know whether CHRF may act as a sponge of miR-489. Cardiomyocytes were transfected with the miR-489 sensor luciferase reporter, along with adenoviral miR-489, CHRF, or β-gal. The luciferase activity showed that CHRF counteracted the effect of miR-489 ( Figure 5I ), suggesting that CHRF is a functional sponge for miR-489. Taken together, these data suggest that CHRF is able to regulate miR-489 levels and activity.
CHRF Is Able to Directly Bind to miR-489
To understand the mechanism by which CHRF regulates the levels of mature miR-489, we tested whether CHRF can interact with miR-489. We compared the sequence of CHRF with that of miR-489 using RNAhybrid and noticed that CHRF contains a target site of miR-489 ( Figure 6A ). We produced a luciferase construct of CHRF RNA (Luc-CHRF-wt) and a mutated form (Luc-CHRF-mut). Luciferase assay revealed that miR-489 could suppress the luciferase activity of CHRF RNA, but it had less effect on the mutated form of CHRF RNA compared with the wild type ( Figure 6B ). These results reveal that CHRF may interact with miR-489 by this putative binding site.
Furthermore, we applied a biotin-avidin pulldown system to test whether miR-489 could pull down CHRF. Cardiomyocytes were transfected with biotinylated miR-489 and then harvested for biotin-based pulldown assay. CHRF was pulled down by miR-489 as analyzed by real-time RT-PCR, but the introduction of mutations that disrupt base-pairing between CHRF and miR-489 ( Figure 6C ) led to the inability of miR-489 to pull down CHRF ( Figure 6D) , indicating that the recognition of miR-489 to CHRF is in a sequence-specific manner. We also used inverse pulldown assay to test whether CHRF could pull down miR-489, using a biotin-labeled specific CHRF probe. miR-489 was precipitated as analyzed by the Northern blot ( Figure 6E ). Taken together, it seems that CHRF is able to directly bind to miR-489.
CHRF Regulates Hypertrophy Through miR-489 and Myd88
Because CHRF can interact with miR-489, we thus tested whether CHRF is able to regulate hypertrophy. Knockdown of CHRF reduced Myd88 levels ( Figure 7A) . The overexpression of CHRF resulted in the upregulation of Myd88 expression and the activation of NF-κB system ( Figure 7B) . CHRF counteracted the effect of miR-489 on Myd88 expression ( Figure 7C ). The luciferase reporter assay showed that CHRF counteracts the inhibitory effect of miR-489 on Myd88 ( Figure 7D ). These results indicated that CHRF may act as endogenous sponge antagomir of miR-489.
Enforced expression of CHRF induced hypertrophic responses, including sarcomere organization and increase in cell surface area and protein/DNA ratio ( Figure 7E ). In the animal model, enforced expression of CHRF increased the apoptosis of cardiomyocytes (Online Figure XIA) . Knockdown of CHRF by siRNA (Online Figure XIB) significantly increased miR-489 levels (Online Figure XIC) and attenuated ANF and β-MHC levels (Online Figure XID) as well as cross-sectional areas (Online Figure XIE) . These results indicate that CHRF is able to regulate hypertrophy. We explored the downstream targets of CHRF in hypertrophy. The modulation of miR-489 ( Figure 7F and 7G) or Myd88 levels ( Figure 7H ) affected hypertrophic responses induced by CHRF, suggesting that Myd88 is a downstream target of CHRF. The target protector of Myd88 attenuated the inhibitory effect of CHRF knockdown on hypertrophic responses ( Figure 7I and 7J). Taken together, these data suggest that CHRF targets the miR-489/Myd88 axis in hypertrophic cascades.
Discussion
Cardiac hypertrophy is a common response to a variety of physiological as well as pathological stimuli and will eventually lead to heart failure. Heart failure is one of the leading causes of hospitalization and death worldwide. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. It is essential to discover impactful therapeutic targets suppressing maladaptive hypertrophy and the consequent heart failure. Our present work identified miR-489 to be an antihypertrophic molecule. We produced miR-489 transgenic mice, and these mice are resistant to hypertrophy. We found that Myd88 is a target of miR-489, and Myd88-deficient mice exhibit reduced hypertrophic responses. Our data further showed that miR-489 inhibits hypertrophy through repressing Myd88. Moreover, we identified that CHRF regulates hypertrophy through miR-489. Our results provide new insights into understanding the pathogenesis of cardiac hypertrophy.
Recent works about miRNAs renovate our understanding about the regulation of cardiac hypertrophy. It is of note that miR-489 transgenic mice exhibit no obvious alterations in phenotype under physiological conditions. However, these mice are resistant to hypertrophy under pathological stimulation with Ang-II. This is consistent with other reports showing that some miRNAs function only under pathological conditions. 33 Because physiological cell growth and pathological hypertrophy can be regulated by the distinct cellular machinery, the underlying mechanism by which a miRNA regulates cell size under physiological condition is an interesting topic for future studies. We have identified through the present work that Myd88 is a target of miR-489. Although most miRNA-mediated suppression of target genes have a seed-match sequence, there is no perfect seed-match sequence between miR-489 and Myd88 3ʹUTR. Many reports also demonstrate that perfect seed-pairing is not mandatory for miRNA target recognition. 34, 35 The 3ʹ pairing, especially the 3ʹ core (positions [13] [14] [15] [16] , is also effective when there is at least a 6mer seed match. 36 The 3ʹ pairing can help compensate for imperfect seed-pairing. 37 In the present study, enforced expression of miR-489 resulted in a reduction of Myd88 on both mouse cardiac myocytes and human cell line HEK293. We also verified the interaction of Myd88 and miR-489 by miR-489 pulldown assay and Ago-2 pulldown experiment. This indicated that the interaction between miR-489 and Myd88 3ʹUTR actually exists in vivo. Our present work uses Myd88-knockout mice to study its role in cardiac hypertrophy and demonstrates that Myd88 is a prerequisite for Ang-II to initiate hypertrophy.
It remains largely unknown as to the molecular mechanism by which Myd88 regulates cardiac hypertrophy. The activation of NF-κB has been documented to stimulate cardiac , and then exposed to Ang-II. Hypertrophy was assessed by cell surface area measurement (I) and protein/DNA ratio analysis (J); *P<0.05.
hypertrophy. For example, MAFbx can convey the signal of cardiac hypertrophy in response to pressure overload. The downregulation of MAFbx inhibits cardiac hypertrophy through inactivation of NF-κB. 38 The interleukin-1 receptor-mediated MyD88-dependent signaling pathway predominately activates NF-κB. Our present results also show that Ang-II treatment can active the NF-κB system, and Myd88-knockout mice reduce the inflammatory response to Ang-II. Thus, it can be speculated that NF-κB may be a downstream target of Myd88 in hypertrophy. Mammalian genomes encode numerous lncRNAs. 39, 40 ln-cRNAs have been defined to have important functions in specific cell types, tissues, and developmental conditions such as chromatin modification, 20 RNA processing, 15 structural scaffolds, 16 and modulation of apoptosis and invasion. 17 Despite the biological importance of lncRNAs, it is not yet clear whether lncRNAs are involved in the regulation of hypertrophy. It has been shown that lncRNAs may act as endogenous sponge RNAs to interact with miRNAs and influence the expression of miRNA target genes. A recent report showed that a muscle-specific lncRNA, linc-MD1, governs the time of muscle differentiation by acting as a competing endogenous RNA in mouse and human myoblasts. 23 Highly upregulated liver cancer may act as an endogenous sponge, which downregulates miR-372 leading to reduced translational repression of its target gene, PRKACB. 31 Transient knockdown and ectopic expression of HSUR 1 directs the degradation of mature miR-27 in a sequence-specific and binding-dependent manner. 32 Our results show that the expression of miR-489 is reduced by the sponge CHRF, which is consistent with a previous report. 31 We speculate that there may exist some mechanisms that can degrade part of the binding miRNA; it is similar to the function of antagomirs that promote miRNA degradation. [41] [42] [43] But the exact mechanism is still unclear. It is also an interesting research topic and we will focus on it in future.
In general, lncRNAs lack strong conservation; many well-described lncRNAs, such as Xist, are poorly conserved. 44 The poor conservation of lncRNAs may be the result of recent and rapid adaptive selection. One report indicates that thousands of poor conservation sequences at the primary sequence level in the mammalian genome have shown evidence of conserved RNA secondary structures. 45 Despite the low conservation of lncRNAs in general, it should be noted that many lncRNAs still contain strongly conserved elements. 46 lncRNAs may have more plastic structure function constraints and conserve only short regions that are constrained by structure or sequence-specific interactions. Our present work reveals a novel function of lncRNA (CHRF) in regulating cardiac hypertrophy. CHRF serves as a sponge of miR-489 regulating the expression of Myd88, which activates hypertrophic responses. CHRF is located in the first intron of Dcc in mouse, and the length is 1843 nt. The full length of CHRF is poorly conserved across species, but it is conserved between species in the binding site of miR-489 (Online Figure XA) . In addition, we also observed an increased expression of CHRF in human heart failure tissue. This indicates that the CHRF may have similar function between the mouse and the human. Our results may provide a new clue for the understanding of lncRNAs-controlled cellular events. The discovery of an lncRNA in cardiac hypertrophy may shed new light on the understanding the complex molecular mechanisms of cardiac hypertrophy.
In summary, our present work identified miR-489 to be an antihypertrophic miRNA. miR-489 is able to influence hypertrophy in cellular and animal models. Our results further reveal that Myd88 is a target of miR-489 in the hypertrophic pathway. Moreover, we demonstrated that CHRF acts as an endogenous sponge RNA and inhibits miR-489 expression and activity. The modulation of miR-489 and CHRF may provide an intriguing approach for tackling cardiac hypertrophy.
